Organometallics
Article
dmpzH, isomer 2), 13.62 (s, 1H, NH, 3,5-dmpzH, isomer 1). The
13C{1H} NMR chemical shifts of isomer 2 are assigned wherever
possible. 13C{1H} NMR (CDCl3, 100.5 MHz): δ 10.8 (CH3), 11.0
(CH3), 13.9 (br, CH3, isomer 2), 14.3 (CH3), 14.9 (CH3), 17.1 (CH3),
17.8 (CH3), 18.0 (CH3, isomer 2), 18.1 (CH3, isomer 2), 19.8 (CH3),
103.6 (br, CH, 3,5-dmpzH, isomer 2), 104.2 (br, CH, 3,5-dmpzH),
105.2 (br, CH, 3,5-dmpzH), 120.3 (ArC), 120.7 (br, ArC, isomer 2),
121.9 (ArCH), 123.6 (br, ArCH, isomer 2), 124.4 (ArCH), 124.5
(ArCH), 125.8 (ArCH), 126.1 (ArCH), 126.6 (ArCH), 127.4 (br,
ArCH, isomer 2), 127.8 (ArCH), 128.5 (ArCH), 129.0 (ArCH), 130.6
(br, ArCH, isomer 2), 131.8 (ArCH), 133.0 (br, ArC, isomer 2), 134.3
(ArC), 134.6 (ArC), 135.3 (br, ArCH), 135.6 (ArCH), 136.3 (ArC),
140.8 (br, ArC, isomer 2), 141.2 (ArC), 142.2 (ArC, isomer 2), 142.5
(ArC), 143.3 (ArC), 143.8 (br, ArC, isomer 2), 146.4 (ArC), 147.0
(ArC), 147.6 (br, ArC, isomer 2), 148.5 (CN). TOF-MS ES+ m/z
(%) [ion]: 965 [κ2{(C,N)Pd}2(μ-(3,5-dmpz))]+, 950 (8) [κ2{(C,N)-
Pd}2(μ-Br)]+, 570 (12) [κ2(C,N)Pd(3,5-dmpzK)]+, 532 (100)
[κ2(C,N)Pd(3,5-dmpz)]+, 434 (74) [κ2(C,N)Pd − H]+, 328 (80)
[LH2‑tolyl]+. ΛM (Ω−1 cm2 mol−1) = 59.7 (10−3 M) in MeCN.
3,5-dmpzH, isomers 1 and 3), 13.50, 13.94 (each br, 2 × 1H, NH, 3,5-
dmpzH, isomer 2), 14.38 (br, 2 × 1H, NH, 3,5-dmpzH, isomers 1 and
3). 19F NMR (376.2 MHz, CDCl3): δ −74.95. TOF-MS ES+ m/z (%)
[ion]: 627 (15) [κ2(C,N)Pd(3,5-dmpzH)2]+, 571 (50) [κ2(C,N)Pd +
3,5-dmpzH + K]+, 531 (100) [κ2(C,N)Pd(3,5-dmpz)]+, 475 (20)
[κ2(C,N)Pd − H + K]+, 330 (95) [LH32‑tolyl]+. ΛM (Ω−1 cm2 mol−1) =
39.0 (10−3 M) in MeCN.
Palladacycle 11. The title complex was prepared from 5 (50 mg,
0.045 mmol) and 3,5-dmpzH (8.7 mg, 0.090 mmol) in CH2Cl2 (20
mL) following the procedure previously outlined for 8. Suitable
crystals of 11·PhMe for SCXRD were grown from a CH2Cl2/toluene
mixture at ambient temperature over a period of several days. Yield:
80% (45.9 mg, 0.061 mmol, 11·0.25C7H8). Mp: 187.7 °C. Anal. Calcd
for PdC32H38N7O3Br·0.25C7H8 (MW: 755.02 + 23.035): C, 52.10; H,
5.18; N, 12.60. Found: C, 52.50; H, 5.24; N, 12.40. IR (KBr, cm−1):
ν(NH) 3391 (m), 3331 (m); ν(CN) 1622 (vs). 1H NMR (CDCl3,
400 MHz): δ 2.00, 2.26, 2.37, 2.41 (each s, 4 × 3H, CH3), 3.75, 3.77,
3.83 (each s, 3 × 3H, OCH3), 5.41, 5.73 (each s, 2 × 1H, CH, 3,5-
dmpzH), 5.78 (d, JHH = 7.3 Hz, 1H, ArH), 6.44 (d, JHH = 7.3 Hz, 1H,
ArH), 6.57−6.63 (m, 2H, ArH), 6.89 (d, JHH = 8.0 Hz, 1H, ArH), 6.93
(t, JHH = 8.1 Hz, 1H, ArH), 7.02 (t, JHH = 7.7 Hz, 1H, ArH), 7.08 (t,
JHH = 7.7 Hz, 1H, ArH), 7.27 (m, 3H, ArH), 7.85 (br, 1H, NH), 8.05
(s, 1H, NH), 12.21, 13.69 (each s, 2 × 1H, NH, 3,5-dmpzH). 13C{1H}
NMR (CDCl3, 100.5 MHz): δ 10.8 (CH3), 11.0 (CH3), 14.1 (CH3),
14.8 (CH3), 54.4 (br, OCH3), 55.4 (br, OCH3), 55.8 (OCH3), 102.9
(ArCH), 105.1 (ArCH), 106.0 (ArCH), 109.5 (ArCH), 111.2 (ArCH),
120.8 (ArCH), 121.2 (ArCH), 121.8 (ArCH), 122.1 (ArCH), 125.0
(ArCH), 125.9 (ArCH), 126.2 (ArC), 126.6 (ArC), 127.0 (ArC), 129.2
(ArCH), 131.4 (ArCH), 134.3 (ArC), 140.7 (ArC), 142.4 (ArC), 145.0
(ArC), 145.7 (ArC), 147.4 (ArC), 148.7 (ArC), 150.3 (ArC), 151.2
(CN). TOF-MS ES+ m/z (%) [ion]: 1043 (27) [{κ2(C,N)Pd}2(μ-
3,5-dmpz) − Me]+, 578 (98) [κ3(C,N,O)Pd(3,5-dmpz)]+, 521 (100)
[κ2(C,N)Pd − H+ + K]+, 481 (88) [κ2(C,N)Pd − H]+, 378 (95)
[LH32‑anisyl]+. ΛM (Ω−1 cm2 mol−1) = 62.6 (10−3 M) in MeCN.
Palladacycle 12. The title complex was prepared from 6 (57.5 mg,
0.048 mmol) and 3,5-dmpzH (9.4 mg, 0.098 mmol) in CH2Cl2 (20
mL) following the procedure outlined previously for 8. Suitable
crystals of 12 for SCXRD were grown from CH2Cl2 over a period of 1
week. Yield: 81% (62.0 mg, 0.079 mmol). Mp (DSC): 219.49 °C
(dec). Anal. Calcd for PdC34H38N7O5F3 (MW 788.14): C, 51.81; H,
4.86; N, 12.44. Found: C, 51.51; H, 5.08; N, 12.05. IR (KBr, cm−1):
ν(NH) 3390 (m), 3346 (m); ν(CN) 1628 (vs), νa(OCO) 1587 (s),
νs(OCO) 1424 (s). The 1H NMR spectrum of 12 revealed the
presence of two isomers in about 1.0:0.04 ratio as estimated from the
Palladacycle 9. The title complex was prepared from 3 (100 mg,
0.077 mmol) and pzH (10.7 mg, 0.158 mmol) in CH2Cl2 (30 mL)
following the procedure previously mentioned for 8. Yield: 80% (80.1
mg, 0.123 mmol). Mp: 185.4 °C. Anal. Calcd for PdC28H30N7Br
(MW: 650.92): C, 51.67; H, 4.64; N, 15.06. Found: C, 51.72; H, 4.69;
N, 15.04. IR (KBr, cm−1): ν(NH) 3417 (m); 3373 (m); ν(CN)
1
1632 (vs). H NMR (CDCl3, 400 MHz): δ 1.70, 2.12, 2.47 (each s, 3
× 3H, CH3), 5.86 (br, 1H, CH, pzH), 5.98, 6.18 (each br, 2 × 1H,
NH), 6.21 (br, 1H, CH, pzH), 6.52−6.56 (m, 2H, ArH), 6.75 (d, JHH
= 7.3 Hz, 1H, ArH), 6.98 (br, 3H, ArH), 7.14 (br d, JHH = 5.8 Hz, 2H,
CH, pzH), 7.20 (br t, JHH = 4.8 Hz, 2H, CH, pzH), 7.27−7.30 (m, 3H,
ArH), 7.38, 7.57 (each br, 2 × 1 H, ArH), 13.20, 14.00 (each br, 2 × 1
H, NH). 13C{1H} NMR (DMSO-d6, 100.5 MHz): δ 17.5 (CH3), 17.8
(CH3), 18.0 (CH3), 18.7 (CH3), 18.8 (br, CH3), 105.5 (br, CH, pzH),
106.9 (CH, pzH), 122.4 (ArC), 123.2 (ArCH), 125.9 (ArCH), 126.4
(br, ArCH), 127.4 (ArCH), 127.5 (ArCH), 127.8 (ArCH), 128.1
(ArCH), 128.3 (br, CH, pzH), 128.8 (ArCH or pzH), 130.8 (CH,
pzH), 131.4 (ArCH), 131.6 (ArCH), 131.8 (ArCH or pzH), 133.6
(ArC), 134.7 (ArC), 135.4 (ArC), 136.0 (ArCH), 136.7 (ArC), 139.2
(br, ArC), 141.2 (ArCH), 144.4 (ArC), 148.7 (CN). The signals of
the minor isomer were detectable only at δ 18.0 and 18.8. TOF-MS
ES+ m/z (%) [ion]: 937 (12) [{κ2(C,N)Pd}2(μ-pz)]+, 515 (35)
[κ2(C,N)Pd + Br]+, 473 (100) [κ2(C,N)Pd − H + K]+, 434 (75)
[κ2(C,N)Pd − H]+, 328 (92) [LH2‑tolyl]+. ΛM (Ω−1 cm2 mol−1) = 51.7
(10−3 M) in MeCN.
1
integrals of CH3 protons of the pyrazole moieties. H NMR (CDCl3,
Palladacycle 10. The title complex was prepared from 4 (96.6 mg,
0.087 mmol) and 3,5-dmpzH (17.1 mg, 0.178 mmol) in CH2Cl2 (30
mL) following the procedure previously mentioned for 8. Suitable
crystals for SCXRD were grown from CH2Cl2 over a period of 1 week.
Yield: 82% (105.5 mg, 0.142 mmol). Mp: 208.4 °C. Anal. Calcd for
PdC34H38N7O2F3 (MW 740.14): C, 55.17; H, 5.17; N, 13.24. Found:
C, 54.94; H, 4.98; N, 13.34. IR (KBr, cm−1): ν(NH) 3423 (m), 3246
(br); ν(CN) 1623 (m), νa(OCO) 1598 (s); νs(OCO) 1412 (m).
400 MHz): δ 1.76 (s, 3H, CH3, isomer 2), 1.92 (s, 2 × 3H, CH3,
isomers 1 and 2), 2.00 (s, 3H, CH3, isomer 1), 2.26 (s, 3H, CH3,
isomer 2), 2.32 (s, 2 × 3H, CH3, isomers 1 and 2), 2.43 (s, 3H, CH3,
isomer 1), 3.75, 3.77, 3.84 (each s, 6 × 3H, OCH3, isomers 1 and 2),
5.41, 5.73 (each s, 2 × 2H, CH, 3,5-dmpzH, isomers 1 and 2), 5.79 (d,
JHH = 7.3 Hz, 2 × 1H, ArH, isomers 1 and 2), 6.44 (d, JHH = 8.0 Hz, 2
× 1H, ArH, isomers 1 and 2), 6.58−6.65 (m, 2 × 2H, ArH, isomers 1
and 2), 6.88−6.94 (m, 2 × 3H, ArH, isomers 1 and 2), 7.00−7.10 (m,
2 × 3H, ArH, isomers 1 and 2), 7.59 (br, 2 × 1H, ArH, isomers 1 and
2), 8.05 (s, 2 × 1H, NH, isomers 1 and 2), 12.51 (s, 1H, NH, 3,5-
dmpzH, isomer 1), 12.72 (s, 1H, NH, 3,5-dmpzH, isomer 2), 14.42 (s,
2 × 1H, NH, 3,5-dmpzH, isomers 1 and 2). One NH proton of the
guanidine moiety was not observed in the 1H NMR spectrum of 12 for
both the isomers, which could be due to a rapid exchange with traces
of water present in CDCl3. 13C{1H} NMR (CDCl3, 100.5 MHz): δ
10.8 (CH3), 11.0 (CH3), 13.9 (CH3) 14.2 (CH3), 14.8 (CH3), 54.4
(br, OCH3), 55.4 (OCH3), 55.8 (OCH3), 103.0 (ArCH), 105.1
(ArCH), 106.1 (ArCH), 106.4 (ArCH), 109.6 (ArCH), 111.2 (ArCH),
1
The H NMR spectrum of 10 revealed the presence of three isomers
in about 1.0:0.57:0.25 ratio as estimated from the integrals of CH3
protons of the pyrazole moieties. 1H NMR (CDCl3, 400 MHz): δ 1.70
(s, 3 × 3H, CH3, isomer 1 (6H), isomer 3 (3H)), 1.83 (s, 3H, CH3,
isomer 2), 1.94 (s, 3 × 3H, CH3, isomer 2 (6H), isomer 3 (3H)), 2.04
(s, 2 × 3H, CH3, isomer 2), 2.10 (br, 2 × 3H, CH3, isomers 1 and 2),
2.14 (s, 3H, CH3, isomer 3), 2.19 (s, 2 × 3H, CH3, isomer 3), 2.30 (br,
3 × 3H, CH3, isomer 1 (6H), isomer 3 (3H)), 2.41 (br, 3H, CH3,
isomer 2), 2.43 (br, 3H, CH3, isomer 1), 2.50 (s, 2 × 3H, CH3, isomers
1 and 3), 5.37 (s, 2 × 1H, CH, 3,5-dmpzH, isomers 2 and 3), 5.47 (br,
2 × 1H, CH, 3,5-dmpzH, isomers 1 and 3), 5.70 (s, 2 × 1H, NH,
isomer 3), 5.73 (br, 2 × 2H, NH, isomers 1 and 2), 5.92 (s, 2 × 1H,
CH, 3,5-dmpzH, isomers 1 and 2), 6.01 (d, JHH = 8.1 Hz, 2 × 1H,
ArH, isomers 1 and 3), 6.19 (d, JHH = 7.3 Hz, 1H, ArH, isomer 2), 6.50
(m, 3 × 3H, ArH, isomers 1−3), 6.72 (d, JHH = 7.3 Hz, 2 × 1H, ArH,
isomers 1 and 3), 6.77 (br, 1H, ArH, isomer 2), 6.94−7.09 (m, 3 ×
2H, ArH, isomers 1−3), 7.20−7.23 (m, 3 × 1H, ArH, isomers 1−3),
7.28−7.30 (br, 3 × 3H, ArH, isomers 1−3), 12.82 (br, 2 × 1H, NH,
1
117.3 (q, JCF = 294.1 Hz, CF3), 120.8 (ArCH), 121.2 (ArCH), 122.0
(ArCH), 122.1 (ArCH), 125.0 (ArCH), 126.0 (ArCH), 126.3 (ArC),
126.8 (ArC), 127.1 (ArC), 129.3 (ArCH), 130.8 (ArCH), 134.5 (ArC),
141.2 (ArC), 142.8 (ArC), 144.7 (ArC), 145.1 (ArC), 145.8 (ArC),
147.6 (ArC), 148.8 (ArC), 150.3 (ArC), 151.2 (ArC), 151.3 (CN),
2
161.7 (q, OC(O)CF3, JCF = 34.2 Hz). The presence of isomer 2 was
detectable only at δ 13.9. 19F NMR (376.2 MHz, CDCl3): δ −75.01.
J
Organometallics XXXX, XXX, XXX−XXX